The regulatory environment for artificial intelligence-enabled devices in the United States

Area of Science:

• Medical Device Regulation
• Artificial Intelligence in Healthcare
• Health Informatics

Background:

• The market for artificial intelligence (AI)-enabled medical devices is expanding rapidly.
• Current US Food and Drug Administration (FDA) regulatory pathways, such as exempt or 510(k) premarket notification, are used for AI device clearance.
• The majority of cleared AI devices are in the radiology and cardiovascular specialties.

Purpose of the Study:

• To highlight the gap between the rapid development of AI-enabled devices and the current US regulatory framework.
• To identify unique challenges posed by AI devices that require specific regulatory attention.
• To emphasize the need for future regulatory guidance concerning AI in medical practice.

Main Methods:

• Analysis of the current regulatory landscape for AI-enabled medical devices in the United States.
• Review of existing US Food and Drug Administration (FDA) clearance pathways (exempt and 510(k)) for these devices.
• Identification of key challenges including AI development, model comprehensibility, and continuous learning.

Main Results:

• The US regulatory environment has not kept pace with the rapid growth of AI-enabled devices.
• Existing FDA guidance does not adequately address the unique challenges of AI devices.
• Liability issues associated with the clinical use of AI-enabled devices remain unaddressed.

Conclusions:

• There is a critical need for updated US Food and Drug Administration (FDA) guidance to address the complexities of AI-enabled medical devices.
• Future regulatory frameworks must consider AI-specific challenges such as continuous learning and clinical implementation.
• Addressing liability is crucial for the responsible integration of AI devices into clinical practice.